Verrica Pharmaceuticals Inc. (VRCA)
CIK 1660334 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 17.2M shares as of Jul 31, 2026 (10-Q). Share count fell from 92.5M to 9.4M between May 7, 2025 and Aug 5, 2025, a pattern consistent with a reverse split (roughly 1-for-10); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Pre Funded Warrant | 4.1M | $0.0001 | — | — |
| Series C Warrants | 3.0M | $6.315 | — | — |
| Series B Warrants | 2.4M | $13.35 | — | — |
| Orbi Med Debt Facility | 51,855 | $23.5541 | — | — |
| Torii Amendment | 50,000 | $95.6 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 50,000 underlying shares, as reported May 14, 2024 (10-Q).
Reported exercise price: $95.6 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 17.2M = 17.2M O/S + 50,000 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 6, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 17.2M | Jul 31, 2026 |
| + Pre Funded Warrant (if exercised) | 4.1M | Jun 30, 2026 |
| + Series C Warrants (if exercised) | 3.0M | Jun 30, 2026 |
| + Series B Warrants (if exercised) | 2.4M | Jun 30, 2026 |
| + Orbi Med Debt Facility (if exercised) | 51,855 | Jun 30, 2026 |
| + Torii Amendment (if exercised) | 50,000 | Jun 30, 2026 |
| Fully diluted estimate | 26.7M | +55.7% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $120.4Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 1 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full VRCA workspace